GlobeNewswire by notified

OP Corporate Bank plc’s Report by the Board of Directors, Financial Statements and Corporate Governance Statement for 2022 published

Share

OP Corporate Bank plc
Stock exchange release
8 March 2023 at 15.00 EET

OP Corporate Bank plc’s Report by the Board of Directors, Financial Statements and Corporate Governance Statement for 2022 published

OP Corporate Bank plc has published its Financial Statements, Report by the Board of Directors and Corporate Governance Statement for 2022. The Financial Statements and Report by the Board of Directors have also been published as an XHTML file in accordance with the reporting requirements of the European Single Electronic Format (ESEF).

The reports are attached to this stock exchange release. They are also available at op.fi – OP Financial Group – To the media – Publications – OP Corporate Bank publications.

The reports are part of OP Financial Group’s Annual Report, which is available at vuosi.op.fi/en/2022.

OP Corporate Bank plc
Board of Directors

Further information:
OP Financial Group’s Investor Relations, IR@op.fi

Media enquiries:
OP Financial Group’s Corporate Communications, tel. +358 10 252 8719, viestinta@op.fi

DISTRIBUTION
Nasdaq Helsinki Ltd
Euronext Dublin (Irish Stock Exchange)
LSE London Stock Exchange
Major media
op.fi

OP Corporate Bank plc is part of OP Financial Group. OP Corporate Bank and OP Mortgage Bank are responsible for OP's funding in money and capital markets. As laid down in the applicable law, OP Corporate Bank, OP Mortgage Bank and their parent company OP Cooperative and other OP Financial Group member credit institutions are ultimately jointly and severally liable for each other's debts and commitments. OP Corporate Bank acts as OP Financial Group's central bank.

Attachments

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

CNH Industrial: Periodic Report on a third $50 million tranche of $300 million Buyback Program29.3.2023 22:30:00 CEST | Press release

London, March 29, 2023 CNH Industrial N.V. (NYSE: CNHI / MI: CNHI) announces that under a third $50 million tranche (the “Third Tranche”) in the framework of its $300 million common share buyback program, the Company completed transactions in the period March 20, 2023 to March 24, 2023, reported in aggregate, as set forth in the table below. After the purchases announced today and considering those previously executed under the Third Tranche, the total invested amount is approximately €20,017,834.02 ($21,418,144.90) for a total amount of 1,496,705 common shares purchased. DateNumber of common shares purchasedAverage price per share excluding feesConsideration excluding fees Consideration (**) excluding fees(€)(€)($) March 20, 2023 139,705 12.9545 1,809,808.42 1,939,571.69 March 22, 2023 183,000 13.6446 2,496,961.80 2,692,973.30 March 23, 2023 256,000 13.4840 3,451,904.00 3,755,326.36 March 24, 2023 262,000 13.3041 3,485,674.20 3,745,356.93 840,705-11,244,348.4212,133,228.28 As of March

Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons29.3.2023 22:19:21 CEST | Press release

Company Announcement COPENHAGEN, Denmark; March 29, 2023 –Genmab A/S (Nasdaq:GMAB) -In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons. The vesting of the restricted stock units granted to Jan G. J. van de Winkel and Anthony Pagano will be subject to forward looking performance criteria and consequently represent the maximum opportunity available if the performance targets have been significantly exceeded. The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish trading in Genmab shares by the company’s managerial employees and their closely associated persons. About Genmab Genmab is an international biotechnology company with a core purpose guiding its unstoppable team to strive towards improving the

Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab29.3.2023 22:10:21 CEST | Press release

Company Announcement COPENHAGEN, Denmark; March 29, 2023 –Genmab A/S (Nasdaq:GMAB) Following Genmab A/S’ Annual General Meeting held on March 29, 2023, the Company’s Board of Directors met to constitute itself. Ms. Deirdre P. Connelly was appointed Chair and Ms. Pernille Erenbjerg was appointed Deputy Chair. It was decided to grant90,054restricted stock units to members of managementand employees of the Company and the Company’s subsidiaries and16,276warrants to the employees of the Company andthe Company’s subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a right and obligation to receive one share in Genmab A/S of nominally DKK 1. The vesting of the restricted stock units granted to the members of executive management will be subject to forward looking performance criteria and consequently represent the maximum opportunity available if the performance targets have been significantly exceeded. The fair value of each restricted stock unit is equa

US healthcare executive Dr. Ninfa Saunders, DHA, MVA, MSN, FACHE and other Board members to be nominated at general meeting; Chris Lindop not standing for re-election.29.3.2023 22:02:33 CEST | Press release

March 29, 2023 Announcement no. 2 US healthcare executive Dr. Ninfa Saunders, DHA,MVA, MSN, FACHEand other Board members to be nominated at general meeting; Chris Lindop not standing for re-election. COPENHAGEN, DENMARK and BOSTON, MA, USA, March 29, 2023, (GLOBE NEWSWIRE) – The Board of Directors of BioPorto A/S (BioPorto or Company) (CPH:BIOPOR) announces that Chris Lindop, Chairman of the Board of Directors, has for personal reasons decided not to stand for re-election at the upcoming ordinary general meeting. The Board plans to appoint current Vice Chairman, John McDonough, as the new Chairman following the AGM on April 27, 2023. “I am proud to have helped shepherd BioPorto through this period of significant change and opportunity,” said Mr. Lindop. “I am very confident in the Board, Management, and entire team as they commercialize NGAL tests for Acute Kidney Injury (AKI) in Europe and pursue approval of the first authorized AKI biomarker in the US.” The Board also announces that